Skip to main content
Top
Published in: Journal of Neural Transmission 5/2016

01-05-2016 | Neurology and Preclinical Neurological Studies - Original Article

Botulinum toxin therapy: reduction of injection site pain by pH normalisation

Authors: Dirk Dressler, Fereshte Adib Saberi, Hans Bigalke

Published in: Journal of Neural Transmission | Issue 5/2016

Login to get access

Abstract

Botulinum toxin (BT) is injected intramuscularily and may produce injection site pain (ISP). We wanted to explore whether the pH value of the reconstituted BT drug contributes to ISP and, if so, what strategies can be applied to reduce it. In part 1 of the study, pH values of different reconstitution solutions and of major BT drugs reconstituted with different reconstitution solutions were assessed. In part 2, the effects of reconstitution with normal saline (NS) and Ringer acetate (RA) were compared intraindividually and in a double blind fashion in 34 patients with blepharospasm. pH values of reconstitution solutions were 5.52 ± 0.02 for NS, 6.98 for RA, 6.31 for Ringer lactate, 6.56 for electrolyte and 5.31 for bacteriostatic solution. pH values for NS-reconstitution were 6.09 ± 0.20 for Botox®, 5.95 ± 0.24 for Dysport® and 5.81 ± 0.18 for Xeomin®. pH values for RA-reconstitution were 6.95 ± 0.03 for Botox®, 7.01 ± 0.02 for Dysport® and 6.87 ± 0.06 for Xeomin®. By using RA instead of NS the pH could be increased by 0.86 for Botox®, by 1.06 for Dysport® and by 1.06 for Xeomin®. 47 % of the patients experienced less ISP when Botox®-RA was given rather than Botox®-NS, 76 % when Xeomin®-RA was given rather than Xeomin®-NS. None of the patients reported a difference in efficacy between NS- and RA-reconstitution. Despite previous reports, reconstituted BT type A drugs show acidic pH values. Normalising these pH values by use of RA instead of NS reduces ISP considerably without sacrificing clincial efficacy.
Literature
go back to reference Alam M, Dover JS, Arndt KA (2002) Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 138:510–514CrossRefPubMed Alam M, Dover JS, Arndt KA (2002) Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 138:510–514CrossRefPubMed
go back to reference Allen SB, Goldenberg NA (2012) Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study. Dermatol Surg 38:867–870CrossRefPubMed Allen SB, Goldenberg NA (2012) Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study. Dermatol Surg 38:867–870CrossRefPubMed
go back to reference Dressler D, Adib Saberi F, Benecke R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249:1729–1732CrossRefPubMed Dressler D, Adib Saberi F, Benecke R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249:1729–1732CrossRefPubMed
go back to reference Sarifakioglu N, Sarifakioglu E (2005) Evaluating effects of preservative-containing saline solution on pain perception during botulinum toxin type-a injections at different locations: a prospective, single-blinded, randomized controlled trial. Aesthetic Plast Surg 29:113–115CrossRefPubMed Sarifakioglu N, Sarifakioglu E (2005) Evaluating effects of preservative-containing saline solution on pain perception during botulinum toxin type-a injections at different locations: a prospective, single-blinded, randomized controlled trial. Aesthetic Plast Surg 29:113–115CrossRefPubMed
go back to reference Söylev MF, Koçak N, Kuvaki B, Ozkan SB, Kir E (2002) Anesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica 216:355–358CrossRefPubMed Söylev MF, Koçak N, Kuvaki B, Ozkan SB, Kir E (2002) Anesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica 216:355–358CrossRefPubMed
go back to reference Truong D, Dressler D, Hallett M (2009) Manual of botulinum toxin therapy. Cambridge University Press, CambridgeCrossRef Truong D, Dressler D, Hallett M (2009) Manual of botulinum toxin therapy. Cambridge University Press, CambridgeCrossRef
go back to reference Vadoud-Seyedi J, Simonart T (2007) Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 156:986–989CrossRefPubMed Vadoud-Seyedi J, Simonart T (2007) Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 156:986–989CrossRefPubMed
go back to reference van Laborde S, Dover JS, Moore M, Stewart B, Arndt KA, Alam M (2003) Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial. J Am Acad Dermatol 48:875–877CrossRefPubMed van Laborde S, Dover JS, Moore M, Stewart B, Arndt KA, Alam M (2003) Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial. J Am Acad Dermatol 48:875–877CrossRefPubMed
Metadata
Title
Botulinum toxin therapy: reduction of injection site pain by pH normalisation
Authors
Dirk Dressler
Fereshte Adib Saberi
Hans Bigalke
Publication date
01-05-2016
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 5/2016
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-016-1522-9

Other articles of this Issue 5/2016

Journal of Neural Transmission 5/2016 Go to the issue

Neurology and Preclinical Neurological Studies - Original Article

Reconstituting botulinum toxin drugs: shaking, stirring or what?